2018—2021年武汉地区33家医疗机构降糖药物使用情况分析  

Analysis of the Application of Hypoglycemic Drugs in 33 Medical Institutions in Wuhan Region from 2018 to 2021

作　　者：卢立 彭偲偲 程静 刘立[1] 宋红萍[1] LU Li;PENG Sisi;CHENG Jing;LIU Li;SONG Hongping(Department of Pharmacy,Wuhan Forth Hospital,Wuhan 430033,China)

机构地区：[1]武汉市第四医院药学部,武汉430033

出　　处：《医药导报》2023年第10期1553-1560,共8页Herald of Medicine

摘　　要：目的 系统分析武汉地区33家医疗机构降糖药物使用情况和发展趋势,为合理使用降糖药物及制定药物政策提供参考。方法 采用回顾性分析方法,对武汉地区33家医疗机构2018—2021年降糖药物的购药金额、用药频度(DDDs)、限定日费用(DDC)、购药金额与DDDs排序比(B/A)进行统计分析。结果 2018—2021年,武汉地区医疗机构共有10大类54种降糖药物供临床使用,胰岛素类连续4年在10大类降糖药中购药金额及DDDs排名第一。新型降糖药物和复方降糖药物的购药金额和DDDs均逐年递增,而传统降糖药物购药金额和DDDs逐年降低。10大类降糖药物购药金额排序中,胰岛素类、复方降糖药及二肽基肽酶4(DPP-4)抑制剂排序前3位;甘精胰岛素、阿卡波糖、门冬胰岛素30、二甲双胍及吡格列酮/二甲双胍复方制剂购药金额连续4年在54种降糖药物中排前10位。10大类降糖药物DDDs排序中,胰岛素类、α-糖苷酶抑制剂及磺酰脲类排序前3位;阿卡波糖、二甲双胍、吡格列酮/二甲双胍复方制剂、门冬胰岛素30、格列美脲、格列齐特及甘精胰岛素DDDs连续4年在54种降糖药物中排前10位。利拉鲁肽、德谷胰岛素及贝那鲁肽的DDC始终位列前4位。甘精胰岛素连续4年在54种降糖药物中B/A最小,2021年仅为0.1。结论 武汉地区33家医疗机构传统降糖药物使用量占优,但各类药物发展趋势不一;新型降糖药物使用量增长迅速;部分降糖药物经济负担较重。Objective To systematically analyze the application of hypoglycemic drugs in 33 medical institutions in Wuhan region from 2018 to 2021 and to provide a reference for the rational use of hypoglycemic drugs and establishing drug prices.Methods A retrospective analysis was used to statistically analyse the consumption sum,DDDs,DDC and B/A on the hypoglycemic drugs in 33 hospitals in the Wuhan region from 2018 to 2021 Results From 2018 to 2021,there were 54 kinds of hypoglycemic drugs in 10 categories for clinical use in medical institutions in Wuhan area.Insulin category ranks first in terms of consumption sum and DDDs among the 10 categories of glucose-lowering drugs for four consecutive years.Consumption sum and DDDs of new hypoglycemic drugs and compound hypoglycemic drugs in Wuhan regional medical institutions have been increasing yearly,while traditional hypoglycemic drugs have been decreasing in the opposite trend.In terms of consumption sum,insulins,compound hypoglycemic drugs and DPP-IV inhibitors were the top 3 in the 10 categories;Insulin glargine,acarbose,insulin aspart 30 injection,metformin and pioglitazone/metformin compound preparation were the top 10 among 54 drugs for 4 years.In terms of DDDs,insulins,a-glucosidase inhibitors and sulfonylureas were the top 3 in the 10 categories;acarbose,metformin,pioglitazone/metformin compound preparation,insulin aspart 30 injection,glimepiride,gliclazide and insulin glargine were the top 10 among 54 drugs for 4 years.In terms of DDC,liraglutide,benaglutide and insulin degludec were always in the top 4.B/A of insulin glargine were the smallest among 54 drugs for 4 years with only 0.1 in 2021.Conclusion The use of traditional hypoglycemic drugs is dominant in 33 medical institutions in the Wuhan area,but the development trends of various drugs were different.New hypoglycemic drugs are growing rapidly,and some hypoglycemic drugs have a heavier economic burden.

关 键 词：降糖药物 购药金额 用药频度 限定日费用 

分 类 号：R977.15[医药卫生—药品]